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The effect of Maras powder 
and smoking on the microRNA 
deregulation of oral mucosa
Objective: This study aimed to investigate the effects of Maras powder (a 
type of smokeless tobacco obtained from Nicotiana rustica Linn and mixed 
with the ashes of wood, especially from oak, walnut or grapevine) on the 
microRNA (miRNA) deregulation of oral mucosa, and it compares these 
effects with those of smoking. Methodology: Oral mucosal samples were 
collected from 74 patients, consisting of 16 nonusers, 26 smokers, and 32 
Maras powder users. Genes associated with oral cancer were selected and 
90 microRNAs targeting these genes were identified. MicroRNA were isolated 
and purified using the microRNA isolation kit. MicroRNA were expressed using 
Fluidigm RT-PCR. Results: A positive correlation between the duration of 
Maras powder use with miR-31 expression levels, and a negative correlation 
between the Maras powder chewing time and miR-372 expression levels 
was found. In addition, there is a negative correlation between the amount 
of Maras powder consumed and expression levels of miR-375, miR-378a, 
miR-145, and miR-10b; moreover, another negative correlation is observed 
between the number of cigarettes consumed and the expression levels of 
miR-23a, miR-23b, miR-203a, miR-200b, and miR-375. However, miR-200b 
and miR-92a levels were downregulated significantly more in Maras powder 
users when compared with smokers and nonusers (p<0.05). Conclusion: 
The results show both chewing Maras powder and smoking have an effect 
on deregulation of miR-200b and miR-92a expressions. This leads to the 
belief that assessing the expression of these two miRNAs is a promising 
noninvasive method of analysis, especially in mutagen exposures. Finally, 
large-scale and high-throughput studies may help to identify an extensive 
miRNA expression profile associated with tobacco use and improve the 
understanding of oral malignancies.





1Gaziantep University, Faculty of Dentistry, Department of Oral and Maxillofacial Surgery, Gaziantep, 
Turkey.
2Bilkent University, Department of Molecular Biology and Genetics, Ankara, Turkey.
Corresponding address:
Betül Taş
Universite Bulvari, Osmangazi mah - Gaziantep 
Universitesi Dis Hekimligi Fakultesi - Ağiz Dis ve Cene 
Hastaliklari Cerrahisi, 27310 - Gaziantep - Turkey.
Phone: 00905303460713 - Fax: 00903423610346
e-mail: betultas@hotmail.com - tasbetul@gmail.com
2020;28:e201903821/7
J Appl Oral Sci. 2020;28:e201903822/7
Introduction
MicroRNAs (miRNAs) are endogenous small 
noncoding RNAs that function in messenger RNA 
(mRNA) silencing and in the post-transcriptional 
regulation of gene expression1. MiRNAs are important 
in various cellular processes, such as proliferation, 
differentiation, cell growth, and cell death2. Recent 
studies have discovered deregulated expression 
of miRNAs in oral infections, periodontal diseases, 
and oral cancer1,3,4. Xie, et al.1 (2011) performed 
a preliminary comparison of healthy and inflamed 
gingiva (10 healthy and 10 inflamed gingiva). They 
found 12 miRNAs, functioning in inflammatory 
processes and expressed differently, and reported 
a probable close relationship between miRNAs and 
periodontal diseases1. Similarly, Nahid, et al.5 (2011) 
found a persistent association between periodontal 
pathogens and miR-146a expression, suggesting 
miRNAs may promote periodontal diseases5. Likewise, 
understanding the relationship between miRNAs and 
oral malignancies has become increasingly important. 
Park, et al.6 (2009) evaluated and compared the 
miRNA expression profiles of oral squamous cell 
carcinoma patients and healthy controls, and this 
group identified two differentially expressed miRNAs 
(miR-200a and miR-125a) in carcinoma patients. In 
addition to the oral cancer, oral precancerous lesions 
also affect deregulation of miRNA expression4.
Tobacco products vary in the way they are 
consumed, for example, as cigarettes, cigars and 
cigarillos, which are smoked; also as smokeless 
tobaccos, such as chewing tobacco, snuffs, and 
dissolvable products. Yet, tobacco is mainly consumed 
in the form of manufactured cigarettes. According to 
the Global Adult Tobacco Survey conducted in 2015, 
smoking prevalence was 27.1% where smokeless 
tobacco use was not included6. However, Akbay and 
Kafas7 (2017) reported that 16.7% of all participants 
were chewing MP, while 36.8% of all tobacco usage 
in South-East Turkey is of smokeless tobacco. The 
smokeless tobacco used in Turkey comes from 
Nicotiana rustica Linn and is called Maras powder 
(MP). To prepare for consumption, it is mixed with the 
ashes of wood – especially oak, walnut, or grapevine 
–, in approximate ratios of 1:2 or 1:3. The ash helps 
the absorption via oral mucosa by creating an alkaline 
environment8. The mixture is placed between the lips 
or the cheeks and gums/teeth and kept in the mouth 
for 5-10 minutes.
Despite the hazardous effects of tobacco on 
health, molecular alterations in the oral mucosa of 
tobacco chewers and smokers have not been fully 
investigated9. Experimental methods revealed miRNA 
expression in oral fibroblasts and oral keratinocytes is 
deregulated by the exposure to tobacco condensate9.
Because of this knowledge, this study hypothesized 
that smokeless tobacco use and smoking can 
deregulate miRNA expression profiles. Therefore, it 
aimed to analyze the expression profiles of 90 miRNAs 
(including miR-92a, miR-200b, miR-31, miR-372, 
miR-375, miR-378a, miR-145 and miR-10b, miR-23a, 
miR-23b, miR-203a, and miR-375) in a cross-sectional 
study to understand how chronic exposure of oral 
mucosa to tobacco affects the miRNA expression.
Methodology
This study was conducted at the Oral and 
Maxillofacial Surgery Department of the Faculty 
of Dentistry at Gaziantep University. Seventy-four 
male participants (aged between 21 and 54 years), 
consisting of 16 nonusers (no history of tobacco use), 
26 smokers and 32 MP users, were included in this 
study. It was confirmed that smokers had never used 
MP and that MP users had never smoked.
This study followed the medical protocol set out 
by the Declaration of Helsinki and received ethical 
approval from Gaziantep University, Clinical Research 
Ethics Committee (2014/431). All participants signed 
a consent form stating their agreement to participate 
in the study. Data pertaining to these individuals were 
collected using a standardized questionnaire, which 
investigated age, sex, and smoking/chewing habits.
Inclusion and exclusion criteria
Volunteers between 18 and 65 years of age with no 
history of disease and acute/chronic inflammation were 
selected. Those who had been receiving a treatment 
regimen for less than 6 months were excluded. Those 
with presence or history of potentially premalignant 
oral lesions or oral cancer, dermatological diseases, 
oral infections, fractured jaw or previous surgery that 
could affect oral health, and those that consumed 
alcohol, narcotics, or tobacco products other than MP 
or cigarettes were also excluded.
The effect of Maras powder and smoking on the microRNA deregulation of oral mucosa
J Appl Oral Sci. 2020;28:e201903823/7
Sample collection
Oral samples were collected by scraping oral 
mucosa in one direction using a brush or surgical 
blade. The samples were stored at −80°C in empty 
specimen containers until being anayzed1. Samples 
were collected from the buccal mucosa for smokers 
and nonusers, and from the application site for MP 
users.
RNA isolation and cDNA synthesis
Genes associated with oral cancer were selected 
based on the literature, and 90 miRNAs targeting these 
genes were identified using the TargetScan and miRDB 
databases. Furthermore, RNU6, Hs_SNORD68_11 
and miRTC control, known to have relatively stable 
expression levels across different cell and tissue 
types10, were used as an internal reference for 
normalization.
MiRNAs were isolated using the miScript primer 
assay kit (Qiagen, Santa Clarita, CA, USA), according 
to the manufacturer’s instructions. Isolated miRNAs 
were reverse transcribed to generate complementary 
DNAs (cDNAs) with the miScript II RT kit (Qiagen, 
Santa Clarita, CA, USA). To increase the amount 
of cDNA, a pre-amplification step was performed 
(miScript PreAMP PCR kit – Qiagen, Santa Clarita, CA, 
USA). cDNA obtained after reverse transcription was 
stored at -20°C until its use.
Real-time PCR was performed using a Rotor Gene 
6000 Real-Time PCR Machine with the miScript SYBR 
Green PCR Kit (Qiagen, Santa Clarita, CA, USA) for 
miRNA expression.
Bioinformatics and statistical analysis
Threshold cycle (Ct) values were obtained for the 
miRNAs and normalized using the internal control 
genes, respectively. All Ct analyses were performed 
using R Programming Language v3.2.2. Four miRNAs 
(hsa-miR-762, hsa-miR-371-5p, hsa-miR-4685-5p and 
hsa-miR-181d-3p) were excluded from the analyses 
for not having adequate Ct values. The expression 
profiles of 86 miRNAs were then analyzed. Due to the 
exponential nature of PCR data, data was transformed 
to log base 2 to achieve a normal distribution. The 
relative differences in expression (miRNA expression 
about the internal controls) were determined using the 
comparative threshold cycle (delta-delta Ct) method. 
Fold change calculations were based on the formula 
2−ΔΔCT. The mean values of the control genes (RNU6, 
Hs_SNORD68_11, and miRTC control) were obtained 
to calculate 2−∆∆CT.
Statistical analysis was performed using SPSS 
Version 22.0 (IBM, NY, USA). Variables were described 
using standard deviation (SD), standard error (SE), the 
range (minimum-maximum), and a 95% confidence 
interval for the mean. The One-way Anova test (F) 
was used to examine the differences between the 
miRNA expression profiles of the three groups. It was 
then followed by Duncan’s post-hoc test for binary 
comparisons. The duration of usage, the amounts 
of MP or numbers of cigarettes consumed, and the 
amount of time that MP is chewed per day and the area 
where it is applied were analyzed using the Pearson’s 
correlation test. p<0.05 was considered statistically 
significant.
Results
All individuals who participated in this study were 
men. The mean age of the individuals was 32.02 
(±8.13) and all study groups were age-homogeneous 
(f=1.371, p>0.05). The intention was to investigate 
the expression profiles of 90 miRNAs; however, four 
miRNAs (miR-762, miR-371-5p, miR-4685-5p, and 
miR-181d-3p) were excluded from the study for not 
having adequate Ct values. The expression profiles of 
the 86 remaining miRNAs were analyzed (Figure 1).
Of the 86 miRNAs, only miR-92a and miR-200b 
showed different expressions between MP users, 
smokers, and nonusers. The mean (±SD) expression 
level of miR-92a was 5.979 (±1.22) in smokers, 
5.343 (±1.62) in MP users, and 6.461 (±1.22) 
in nonusers (Figure 2), and the difference was 
statistically significant between the groups (f=4.790, 
p=0.011). Post-hoc analysis identified no significant 
difference between smokers and nonusers for miR-
92a expression (p>0.05), while that of MP users 
was significantly different from that of smokers and 
nonusers (p<0.05) (Table 1).
The mean (±SD) expression level of miR-200b 
was 2.998 (±0.95) in smokers, 2.344 (±0.95) in MP 
users, and 3.127 (±1.04) in nonusers (Figure 3). The 
difference in miR-200b expression was statistically 
significant between the groups (f=3.606, p=0.032). 
Post-hoc analysis identified miR-200b significantly 
altered in MP users compared with nonusers (p<0.05).
The mean duration of MP use was 9.68 (±5.59) 
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years, while the mean consumption amount was 0.64 
(±0.46) packets per day. In addition, MP is chewed for 
81.40 (±43.79) minutes per day. The mean duration 
of smoking was 13.34 (±8.02) years, while the mean 
consumption amount was 1.00 (±0.32) packet per day.
It was determined that the duration of MP use 
was positively correlated with miR-31 expression 
(r=0.444, p=0.016) and the MP chewing time per day 
was negatively correlated with miR-372 (r=−0.628, 
p=0.005).
While the consumption amount of MP was 
negatively correlated with miR-375 (r=−0.354, 
p=0.047), miR-378a (r=−0.390, p=0.03), miR-145 
(r=−0.356, p=0.046) and miR-10b (r=−0.357, 
p=0.045) expression, it was positively correlated with 
miR-138 expression (r=0.484, p=0.03).
The amount of cigarettes consumed was negatively 
correlated with miR-23a (r=−0.428, p=0.033), miR-
23b (r=−0.441, p=0.027), miR-203a (r=−0.522, 
p=0.008), miR-200b (r=−0.410, p=0.042), and miR-
375 expression (r=−0.475, p=0.016).
Figure 1- A heat map representing microRNA expression in nonusers, MP users and smokers. The clustering tree showing the concordance 
between miRNAs shown in the Y axis. Red tones on the heat map indicate higher expression levels than the median, while green tones 
show lower expression levels than the median
Figure 2- Boxplot of One-way Anova results for miR-92a 
expression
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Discussion
Tobacco use (via smoking cigarettes or other 
forms of exposure to tobacco constituents) is closely 
associated with cardiovascular and respiratory 
diseases. It is also the most important risk factor for 
cancer and is responsible for the increased risk of 
death from all causes11. Besides, tobacco use affects 
inflammatory processes and causes dysplastic changes 
in oral tissues by changing the apoptotic function. 
A dysfunctional apoptotic system can contribute to 
the pathogenesis of many diseases, including oral 
pathologies10. MP causes genotoxic changes in oral 
mucosa10,12. An epidemiological study revealed that 9% 
of 80 individuals using MP had dysplasia, carcinoma 
in situ, and cancer correlated with the duration of 
consumption13.
MP consumption is rare among women in Turkey. 
Therefore, only male subjects were included in our 
study. Concerning this topic, Akbay and Kafas8 (2017) 
reported that among participants using MP, 1.4% were 
women and 25.1% were men.
Tobacco products modulate the turnover of 
epithelial and mesenchymal tissues14 and inhibit 
cell apoptosis, playing a significant role in oral 
carcinogenesis15. Bhat, et al.10 (2018) reported that 
tobacco use alters miRNA expression in oral cells. This 
leads us to investigate the miRNA expression of oral 
mucosa in two frequently used forms of tobacco. To 
the best of our knowledge, we are the first group to 
investigate the effect of MP use on miRNA expression. 
From the 90 miRNAs analyzed, only miR-92a and 
miR-200b showed different expressions between MP 
users, smokers, and nonusers. The downregulation 
of the miR-200 family is allegedly a sign of inhibitory 
effects on cell proliferation, invasion, and metastasis 
and functions as a tumor suppressor16. In our study, 
the mean expression level of miR-200b was lower 
in MP users than in smokers and in nonusers, and 
a significant difference was observed between MP 
users and nonusers. Similar to our findings, Bhat, 
et al.10 (2018) determined that miR-200b found to 
be downregulated in oral keratinocytes exposed to 
cigarette smoke. MiR-92a is suggested to serve as an 
oncogene or tumor suppressor in different cancers. In 
this study, the mean expression level of miR-92a was 
lower in MP users than in smokers and in nonusers, and 
there was a significant difference between MP users 
and smokers, and between MP users and nonusers.
Our results showed miR-31 is positively correlated 
with MP use, similar to those of Bhat, et al.10 (2018), 
who found upregulation of miR-31 in smokeless 
tobacco-treated oral cells. MiR-31 is also upregulated 
in oral premalignant epithelium and epithelial dysplasia 
and in several neoplasms, including head and neck 
cancers17.
The number of cigarettes consumed was negatively 
correlated with miR-23a, miR-23b, miR-203a, miR-
200b, and miR-375 expression. Many studies have 
been conducted to evaluate the effect of smoking 
on miRNA regulation. Smoking has been reported to 
reduce miR-203a expression in rectal cancer18. Also, 
Ma, et al.19 (2014) stated that the dysregulation 
miRNA N Mean SD F p
miR-200b
Smoker 25* 2.998 0.958
3.606 0.032MP 32 2.344 0.950
Nonuser 16 3.127 1.042
miR-92a
Smoker 25* 5.979 1.229
4.790 0.011MP 32 5.343 1.620
Nonuser 16 6.461 1.229
*Results of one sample were missing for related miRNAs
Table 1- Differentially expressed miRNAs related to duration and consumption of MP and smoking
Figure 3- Boxplot of One-way Anova results for miR-200b 
expression
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of miR-23a and miR-23b may be implicated in 
the progression of human gastric cancer, and the 
combined expression of miR-23a and miR-23b seems 
to be a valuable marker for prognosis of this disease19.
This study, interestingly, determined that both the 
amount of MP and number of cigarettes consumed 
were negatively correlated with miR-375. Similarly, 
Conickx, et al.14 (2017) showed the expression of miR-
375 decreased significantly in the lungs of mice after 
exposure to cigarette smoke for 24 weeks13.
MiRNA profiling was performed on oral mucosa, 
although blood could be tested to determine the 
correlation between tissue and blood. In addition, 
histological analysis could be conducted to support 
our findings. The sample size is our limitation in this 
study, as MP is usually consumed with cigarettes and/
or is used as an alternative to smoking. Multicenter 
longitudinal studies investigating larger sample sizes 
are needed to generalize our findings. In future 
studies, examining the changes in existing miRNA 
expressions after the cessation of tobacco use will 
also be necessary.
Conclusions
The results of our study show the use of MP and 
smoking deregulate miRNA expression (miR-200b and 
miR-92a). This leads to the belief that assessing miRNA 
expression is a promising noninvasive method of 
analysis, especially in the case of mutagen exposures. 
Finally, large-scale and high-throughput studies 
may help to identify extensive miRNA expression 
profiles associated with tobacco use and improve the 
understanding of oral malignancies.
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